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Rho-associated, coiled-coil-containing protein
kinase 1 as a new player in the regulation of
hepatic lipogenesis
Non-alcoholic fatty liver disease
(NAFLD), an umbrella term that encom-
passes liver pathologies ranging from
steatosis to non-alcoholic steatohepatitis,
is the most common form of chronic
liver disease in the world. The prevalence
of NAFLD varies from 20 to 40% in
Western countries and 12–30% in Asia.
Although NAFLD represents a meta-
bolic syndrome affecting the liver, it is also
a risk factor for various diseases, including
insulin resistance, hyperlipidemia, hyper-
tension, chronic kidney disease and type 2
diabetes. Notably, NAFLD is highly preva-
lent among type 2 diabetes patients, and
patients with NAFLD and type 2 diabetes
have a higher risk of progression to cirrho-
sis or liver cancer compared with those
who do not have type 2 diabetes.
Over the past several decades,
researchers have strived to elucidate the
pathogenesis of NAFLD and identify
therapeutic targets, yet there are no drugs
approved for treating this condition. A
signiﬁcant challenge to developing a
NAFLD treatment is the intricacy of the
disease; its progression varies among
individuals with diverse genetic back-
grounds, environments, microbiomes and
comorbidities. Thus, further research is
still required to complete the molecular
puzzle that underlies the pathogenesis of
NAFLD, and advance the development
of effective treatments for NAFLD.
Huang et al.1 recently reported con-
vincing evidence in the Journal of Clini-
cal Investigation that hepatic rho-
associated coiled-coil-containing kinase 1
(ROCK1) contributes to high-fat diet
(HFD)-induced hepatic lipogenesis
through the inhibition of the energy
guardian, adenosine 5´-monophosphate-
activated protein kinase (AMPK).
ROCK1 is a serine/threonine protein
kinase belonging to the protein kinase A,
G and C families that are expressed in
most tissues. Over the past decade, accu-
mulating evidence has shown that
ROCK1 is a multifunctional protein reg-
ulating various cellular functions, includ-
ing cell motility, proliferation, cytoskeletal
rearrangement and gene expression. Dys-
regulation of ROCK1 signaling has been
found in several metabolic syndrome-
related diseases, including obesity and
type 2 diabetes. However, a holistic
understanding of the role of ROCK1 in
the pathogenesis of these conditions
remains elusive.
To investigate whether ROCK1 is asso-
ciated with insulin resistance and fatty
liver diseases, the authors used mice fed
either a normal chow diet or HFD for
several weeks. Hepatic ROCK1 levels and
activity were enhanced in HFD-fed mice
compared with control mice. A similar
ﬁnding was obtained in ob/ob (leptin
deﬁcient) and db/db (leptin receptor deﬁ-
cient) mice aged 10 weeks, as well as
humans with fatty liver disease, in which
the hepatic ROCK1 level was found to
be increased compared with that in con-
trols. Intriguingly, liver-speciﬁc ROCK1-
deﬁcient mice (L-ROCK1-/-), but not
control mice, showed a decrease in body-
weight concomitant with decreasing lipid
accumulation in epididymal and mesen-
teric fat, increased energy expenditure,
and higher locomotor activity after being
fed a HFD, resulting in the prevention of
diet-induced obesity. In line with these
observations, L-ROCK1-/- mice main-
tained on a HFD did not engender the
insulin resistance often promoted by obe-
sity.
To further support these ﬁndings, the
researchers generated mice expressing a
constitutively active form of ROCK1 in
the liver (L-CA-ROCK1). As expected,
HFD worsened obesity and insulin resis-
tance in L-CA-ROCK1 mice compared
with the control mice. Although locomo-
tor activity was not changed between
control and L-CA-ROCK1 mice, energy
expenditure was demonstrably decreased
in L-CA-ROCK1 mice.
Obesity is closely associated with the
development of NAFLD. Indeed, 70% of
overweight individuals, 70% of diabetes
patients and up to 90% of morbidly obese
individuals have been found to have
NAFLD2. In principle, hepatic lipid accu-
mulation results from disruption of the
orchestrated balance of lipid metabolism,
which is governed by a physiological quar-
tet: uptake of circulating fatty acids, fatty
acid oxidation, triglyceride export as very
low-density lipoprotein and hepatic de
novo lipogenesis (DNL). Looking at lipid
metabolism in the liver of bodyweight-
matched L-ROCK1-/- mice and control
mice fed with a HFD, the authors con-
cluded that hepatic ROCK1 plays a pivotal
role in obesity-induced hepatic steatosis
through upregulation of lipogenesis-
related genes that promote hepatic DNL.
Consistently, the expression levels of genes
encoding lipogenic enzymes were
increased in L-CA-ROCK1 mice, but not
control mice, after being fed a HFD. Of
note, unlike DNL, the regulation of fatty
acid oxidation, fatty acid uptake and
triglyceride secretion was not altered by
hepatic ROCK1 activity, as judged by the
expression level of related genes and the
serum lipid proﬁle in L-ROCK1-/- and L-
CA-ROCK1mice.
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COMMENTARY
De novo lipogenesis, a fundamental
function of the liver, is the biochemical
process of fatty acid synthesis from
acetyl-coenzyme A obtained from carbo-
hydrate metabolism (e.g., glycolysis). In
general, dietary carbohydrates not stored
as glycogen or oxidized in response to
the immediate energy demand are to be
subjected to DNL. Therefore, excess car-
bohydrate intake could prime DNL.
Although DNL is closely intertwined
with the pathogenesis of NAFLD, this
relationship varies widely depending on
the experimental conditions (e.g., popu-
lation, method of hepatic steatosis assess-
ment etc.). In addition, the issue of
whether DNL is attributable to HFD
remains controversial3. Furthermore,
although it is known that obesity is the
strongest risk factor for NAFLD, DNL is
not an integral contributor to obesity.
Therefore, it is likely that obesity,
NAFLD and DNL represent vertexes of a
triangle, but the connections among the
vertexes are not well understood. How-
ever, as shown by Huang et al.1, these
connections could potentially be clariﬁed
by understanding the role of ROCK1.
How hepatic ROCK1 potentiates DNL
in HFD-fed mice remains a fascinating
biological question. The researchers
focused on the endocannabinoid system
to attempt to address this question. Endo-
cannabinoids are endogenous agonists of
cannabinoid receptors (CB1R and CB2R)
that elicit a broad spectrum of physiologi-
cal responses. So far, two arachidonic acid
derivatives, anandamide and 2-arachido-
noylglycerol, have been identiﬁed as endo-
cannabinoids. Osei-Hyiaman et al.4
previously reported that hepatic CB1R is
involved in hepatic DNL, leading to the
hypothesis that the lipogenic activity of
hepatic ROCK1 is regulated by the endo-
cannabinoid system. Examining ROCK1
activity in response to the endocannabi-
noid system in vitro and in vivo showed
that this system contributes upstream sig-
naling components that lead to the activa-
tion of ROCK1 followed by hepatic DNL.
The apparent role of the endocannabi-
noid system in ROCK1-mediated hepatic
DNL ties into the involvement of AMPK
in this process, as CB1R and AMPK are
part of a signaling network in the regula-
tion of hepatic DNL. However, the
molecular mechanisms underlying the
CB1R–AMPK axis remain unclear.
Huang et al.1 successfully showed that
ROCK1 ﬁlls a gap between CB1R and
AMPK in the signaling pathway. More
speciﬁcally, endocannabinoids known to
be secreted from hepatic stellate cells
upon HFD activate ROCK1 in hepato-
cytes, resulting in the inhibition of
AMPK, followed by the upregulation of
lipogenesis.
The research summarized here undo-
ubtedly extends our understanding of
NAFLD pathogenesis (Figure 1). How-
ever, further research is still required to
fully clarify the underpinnings of this
process.
First, what lipid species were predomi-
nantly accumulated through ROCK1-
mediated lipogenesis in the liver? In the
current conceptual framework, a causa-
tive pathogenic driver of NAFLD
involved an accumulation of toxic lipid
species, which provoke endoplasmic
reticulum stress and hepatocellular
injury, which then predispose the liver to
cirrhosis and hepatocellular carcinoma
after ﬁbrogenesis and genomic instabil-
ity. Elucidating the speciﬁc toxic lipid
species involved will likely reveal new
therapeutic opportunities, where chang-
ing the lipid quality as opposed to the
quantity can help prevent NAFLD.
Second, it is as yet unknown how the
endocannabinoids–ROCK1 axis inhibits
AMPK. Huang et al.1 did not feel that
ROCK1 per se is a novel direct AMPK
inhibitor, as they could not identify an
interaction between ROCK1 and AMPK.
Although this suggests indirect suppres-
sion of AMPK by ROCK1, the underlying
molecular mechanisms require further
investigation. One possibility is a rear-
rangement of AMPK dynamics. To date, a
growing body of evidence suggests that,
under certain conditions, physiological
input encoded in the pattern of spatiotem-
poral dynamics of AMPK seems to be cru-
cial in determining the speciﬁc
downstream AMPK function5. AMPK
dynamics can be altered by various factors,
including the organelle morphology, num-
ber and size of signaling platforms on
membrane, and molecular congestion in
the cytosol, all of which are attributed, at
least partially, to the lipid proﬁle. There-
fore, the molecular environment created
by ROCK1 might negatively regulate
AMPK, leading to lipogenesis. Further
research is required to clarify this process.
Finally, it is unclear why hepatic
ROCK1 deﬁciency prevents HFD-induced
obesity in mice. The study authors
hypothesize that hepatokines might be
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Figure 1 | Proposed model of rho-associated coiled-coil-containing kinase 1 (ROCK1)-mediated lipogenesis in the liver. Upon high-fat feeding, the
endocannabinoids secreted from hepatic stellate cells provoke ROCK1 activation through a cannabinoid receptor on the surface of hepatocytes.
Once ROCK1 is activated, adenosine 5´-monophosphate-activated protein kinase (AMPK) was shut down through an unknown mechanism, leading
to potentiation of lipogenesis in the hepatocytes. CB1R, cannabinoid receptor 1.
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involved. Another possibility is a reorgani-
zation of the blood metabolome, whose
functions include not only contributing to
the building blocks of a cell, but also pro-
ducing signaling cues to regulate various
signaling pathways. Disentangling the
mechanisms underlying the prevention of
obesity through ROCK1 deﬁciency will
provide further insight into critical aspects
of cell biology, and might also lead to per-
sonalized medicine options for the treat-
ment or prevention of NAFLD.
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